“Deborah agreed to take part in a trial as she was keen to help other cancer patients in the future. "If taking part in a trial means others might be helped then I’m very happy with that."
A trial looking at neratinib and capecitabine for breast cancer that has spread (NALA)
This trial is comparing neratinib and capecitabine with lapatinib and capecitabine for breast cancer that has spread (secondary breast cancer). The trial is for people whose secondary breast cancer has large amounts of the protein HER2 (HER2 positive).
Doctors can use trastuzumab (Herceptin) to treat HER2 positive secondary breast cancer. If this stops working they can try other treatments. Lapatinib and capecitabine is one combination of drugs that they can use. Capecitabine is a chemotherapy drug.
Neratinib is a type of biological therapy. It is also a cancer growth blocker.
The researchers want to compare capecitabine and lapatinib with capecitabine and neratinib to find out which is best for HER2 positive secondary breast cancer.
Who can enter
You may be able to enter this trial if
- You have breast cancer that has spread to another part of your body
- Your cancer has large amounts of the
HER2 protein(HER2 positive)
- You have already had 2 different types of treatment for your HER2 positive cancer
- You have at least 1 area of cancer that can be measured on a scan
- Your heart works well enough (your doctor will test for this)
- You are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
- You have satisfactory blood tests results
- You are willing to use reliable contraception during treatment and for a month afterwards (for women) and for 3 months afterwards (for men) if there is any chance you or your partner could become pregnant
- You are at least 18 years old
You cannot enter this trial if
- Your cancer has spread to your brain and is causing symptoms. If you have been taking the same dose of steroids for the past 2 weeks and you have no symptoms you may be able to take part
- You have already had capecitabine, lapatinib, neratinib or similar drugs
- You have had any
anthracycline chemotherapy drugssuch as epirubicin or doxorubicin and the total dose is more than a certain amount (your doctor can tell you about this)
- You have had major surgery in the past month
- You have had any anti cancer treatment in the past 3 weeks (or 2 weeks for radiotherapy)
- You have had a heart attack in the last year or have other certain heart conditions (the trial team can tell you about this)
- You have an infection
- You have had another cancer in the past 3 years apart from some
early cancersor any other cancer that has been successfully treated
- You have diarrhoea
- You have hepatitis B or hepatitis C
- You are known to have low levels of a protein called DPD
- You are sensitive to any of the drugs used in this trial, or their ingredients
- You are not able to or don’t want to swallow tablets
- You have any other medical condition that could affect you taking part in this trial
- You are breast feeding or pregnant
This is an international phase 3 trial. It will recruit 600 people. It is a randomised trial. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.
- People in group 1 have neratinib and capecitabine
- People in group 2 have lapatinib and capecitabine
Neratinib is a tablet. You take 6 tablets once a day in the morning with food.
When you start taking neratinib you will also take tablets to stop diarrhoea. Your doctor will tell you when and how to take them. You may need to continue taking the tablets to stop diarrhoea while taking neratinib. Your doctor will talk to you about this.
Lapatinib is a tablet. You take 5 tablets once a day, an hour before or after breakfast.
Capecitabine is a tablet. Your doctor will tell you how many you need to take. You take them twice a day. You take them within 30 minutes before or after having your breakfast and evening meals. You take them for 2 weeks and then have a week of not taking them.
You continue treatment as long as it is helping you and the side effects aren’t too bad.
People having neratinib will have an electronic diary to fill in for the first 8 weeks of treatment. In the diary you record
- When you take your neratinib
- How many times you open your bowels each day
- How often you take medication for diarrhoea
The trial team will ask you to fill out some questionnaires before you start treatment, every 6 weeks during treatment and after you finish treatment. The questionnaires will ask about side effects and how you’ve been feeling. This is called a quality of life study.
If you want to take part in this trial, the researchers will ask to take a new sample of your cancer (a
You see the doctor to have some tests before taking part in this trial. These tests include
- A physical examination
- Blood tests
- Tissue sample (
biopsy), if needed
- Heart trace (
- Heart scan (
- CT scan or MRI scan
During treatment you see the doctor once a week for 3 weeks to see how you are. And then every 4 weeks for a physical examination and blood tests.
You have the heart trace and heart scan every 6 weeks for 3 months, then every 4 months after that.
You have a CT scan or MRI scan every 6 weeks until your cancer gets worse.
You see the doctor within 3 days after treatment finishes and then the doctor will telephone you 1 month after your last trial treatment to see how you are doing. The doctor will then telephone you every 3 months for the rest of your life or until you decided to withdraw from the trial.
The most common side effects of neratinib are
- Rash, dry and itchy skin
- Feeling or being sick
- Tummy (abdominal) pain
- Sore, dry mouth
- Sore throat
- Muscle spasms
- Loss of appetite
Your doctor will talk to you about the possible side effects before you agree to take part in this trial.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Steven Chan
NIHR Clinical Research Network: Cancer